Oscar Health OSCR · NYSE
$31.88 -4.75% (-$1.59)
Summary
77 / 100 · Bulios Score
What speaks for it
- Revenue grew by 42% a year over the last 3 years.
- It earns 23 USD a year on every 100 USD of invested capital.
- It holds more cash than debt: $4.08B against $431.6M.
- Analysts expect revenue to grow by 59% this fiscal year.
What to watch
- The share price is above the Bulios Fair Price.
- Out of every 100 USD of revenue, only 3.6 USD is left as net profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 15.8 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 82% a year over 5 years. Over the last 3 years it grew by 42% a year. For the next fiscal year analysts expect revenue to grow by 59%.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 55 USD
- Sales and administration 41 USD
- Taxes and other 0.5 USD
- Net profit 3.6 USD
Net profit, industry median (Medical - Healthcare Plans) 2.3 USD
Out of every 100 USD of revenue, 3.6 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 4
- Hold 8
- Sell 1
Today's price within the analysts' price targets
The average target of $34 is 6.6% above today's price. 31% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.